替考拉宁治疗医院获得性肺炎影响预后的因素分析

发布时间：2018-12-29 15:37

【摘要】：目的探讨替考拉宁治疗耐甲氧西林金黄色葡萄球菌医院获得性(MRSA)肺炎预后的影响因素,为临床治疗提供依据。方法回顾性分析医院呼吸重症科替考拉宁治疗医院获得性肺炎患者35例,收集临床资料,分析影响预后的因素,采用SPSS17.0软件对数据进行统计处理。结果 35例患者中经验治疗18例占51.43%,目标治疗17例占48.57%,替考拉宁治疗天数经验治疗组明显长于目标治疗组,14d死亡例数经验治疗组明显低于目标治疗组,经验治疗组治疗成功例数明显多于目标治疗组,差异有统计学意义(P0.05);35例医院获得性MRSA患者中治疗失败15例占42.85%,其中13例死亡,病死率37.14%。结论影响替考拉宁治疗医院获得性肺炎预后的因素有年龄、治疗时间及经验性应用替考拉宁,经验性应用替考拉宁可降低病死率。
[Abstract]:Objective to investigate the prognostic factors of teicoplanin in the treatment of methicillin-resistant Staphylococcus aureus nosocomial (MRSA) pneumonia. Methods 35 cases of nosocomial pneumonia treated with teicoplanin were retrospectively analyzed. The clinical data were collected and the factors influencing the prognosis were analyzed. The data were analyzed by SPSS17.0 software. Results among the 35 patients, 18 were treated with experience (51.43) and 17 with target therapy (48.57). The days of teicoplanin treatment in the experience group were significantly longer than those in the target treatment group, and the number of death cases in the experience treatment group was significantly lower than that in the target treatment group. The number of successful cases in the experiential treatment group was significantly higher than that in the target treatment group (P0.05). Of the 35 patients with hospital acquired MRSA, 15 cases were failed in treatment, 13 cases died, and the mortality was 37.14%. Conclusion the factors influencing the prognosis of tiicoplanin in the treatment of nosocomial pneumonia are age, treatment time and empirical application of teicoplanin, and the empirical application of teicoplanin to reduce the mortality.
【作者单位】：郑州大学第一附属医院呼吸重症科;郑州大学第一附属医院血液科;
【基金】：国家自然科学基金资助项目(81000224)
【分类号】：R563.1

【相似文献】